Table 1.

Photosensitivity reactions to vandetanib reported in the literature

First author, year (Ref.)	Trial design	Vandetanib arm	Control arm	Enrollment no.	Sample size	Underlying cancer
Katsuyuki Kiura, 2008 [9]	Phase IIa	100-300 mg/day	N/A	53	12	NSCLC
Heidi Kong, 2009 [11]	N/A	N/A	N/A	N/A	1	Recurrent brain tumor
Chih-Hsiang Chang, 2009 [10]	Phase II	300 mg/day	N/A	N/A	1	HCC
Damien Giacchero, 2012 [12]	Phase II/III	300 mg/day	Placebo	63	23	Metastatic thyroid cancer